RECRUITINGOBSERVATIONAL
IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy
About This Trial
Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.
Who May Be Eligible (Plain English)
Who May Qualify: Patient with otherwise refractory symptoms of gastrointestinal (GI) motor disorders.
\-
Who Should NOT Join This Trial: Inability to receive intravenous immunoglobulin.
\-
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria: Patient with otherwise refractory symptoms of gastrointestinal (GI) motor disorders.
\-
Exclusion Criteria: Inability to receive intravenous immunoglobulin.
\-
Locations (1)
University of Louisville
Louisville, Kentucky, United States